Alex Biese

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.

Whole-pelvic radiation conferred a 67% lower risk of all-cause mortality among patients younger than 65 with unfavorable-risk prostate cancer.

Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study.

Patients with high-risk early-stage non-small cell lung cancer who underwent surgery reported similar quality of life outcomes as those who had radiation.

Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.

When it comes to high blood sugar, cancer and diabetes can create a “vicious cycle,” as one expert explained.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

Nearly 40% of AYA cancer survivors visit an emergency department within five years after diagnosis for reasons including headache and chest pressure.

As up to 42% of patients with cancer may be using cannabis, one expert spoke to CURE® to separate cannabis myths from reality.

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

The FDA has approved Hercessi for the adjuvant treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The combination of bispecific antibody CTX-009 and chemotherapy received Fast Track Designation for advanced, previously treated biliary tract cancers.

Research has shown aspirin use to be associated with lower rates of metastasis for some patients.

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.

The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech.

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.

Researchers have found that treatment with antibody-drug conjugates is associated with fatigue among patients with breast cancer.

SKB264 led to durable responses and a manageable safety profile in patients with gastric or gastroesophageal junction cancers, an expert said.

The blood pressure medication enalapril did not prevent cardiotoxicity among patients with cancer being treated with chemotherapy.

Compared to other treatments, patients’ testosterone levels return to baseline levels faster following treatment with Orgovyx.

Radiation followed by mastectomy and immediate breast reconstruction “holds tremendous promise,” as one researcher explained.

An expert explains the necessity of managing patients’ testosterone levels while treating prostate cancer.

There is no difference in recovery, complication or cost between the two most common surgical approaches for esophageal cancer.

An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.

Some patients with limited-stage small cell lung cancer experienced overall survival benefits and progression-free survival via treatment with Imfinzi.